Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: A randomized open clinical trial

Clinical Neuropharmacology

Volumn 35, Issue 2, 2012, Pages 61-66

  Pintor, Luis ^a   Valldeoriola, Francesc ^a   Baillés, Eva ^a   Martí, María José ^a   Muñiz, Armando ^a   Tolosa, Eduard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

clozapine; Parkinson disease; psychosis; ziprasidone

Indexed keywords

CLOZAPINE; ENTACAPONE; PAROXETINE; PRAMIPEXOLE; ZIPRASIDONE;

AGED; ANKLE EDEMA; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DELUSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HALLUCINATION; HUMAN; HYPERSALIVATION; INSOMNIA; LEUKOCYTE COUNT; MALE; MALLEOLAR EDEMA; PARKINSON DISEASE; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; THINKING IMPAIRMENT; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PARKINSON DISEASE; PIPERAZINES; PSYCHOTIC DISORDERS; SINGLE-BLIND METHOD; THIAZOLES; TREATMENT OUTCOME;

EID: 84858798987     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31824d5115     Document Type: Article

References (41)

1. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004;63:293-300. (Pubitemid 38971129)
2. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009;24:2175-2186.
3. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008;25:665-682.
4. Durán-Ferreras E, Chacón JR. Treatment of psychosis in Parkinson. Rev Neurol 2009;48:645-653.
5. CollaborativeWorking Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998;59(suppl 12):S23-S27.
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. (Pubitemid 41345943)
7. Valldeoriola F, Nobbe FA, Tolosa E. Treatment of behavioural disturbances in Parkinson's disease. J Neural Transm 1997;51:175-204. (Pubitemid 28055700)
8. Frieling H, Hillemacher T, Ziegenbein M, et al. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007;17:165-171. (Pubitemid 44779199)
9. Daniel DG, Copeland LF. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Exp Opinion Invest Drugs 2000;9:819-828. (Pubitemid 30175648)
10. Durán-Ferreras E, Alvarez-López M, García-Moreno JM, et al. Ziprasidone in Parkinsonian dopamine psychosis. Rev Neurol 2008;46:476-480. (Pubitemid 351767899)
11. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in Parkinsonian patients with psychosis. Clin Neuropharmacol 2005;28:111-114. (Pubitemid 40923408)
12. Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-191. (Pubitemid 46073393)
13. Micheli F, Taubenslag N, Gatto E, et al. Ziprasidone and psychosis in Parkinson disease. Clin Neuropharmacol 2005;28:254.
14. Miyasaki JM, Shannon K, Voon V, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002. (Pubitemid 44044781)
15. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
16. Hoehn MM, Yahr MD. Parkinsonism: onset progression and mortality. Neurology 1967;17:427-442.
17. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatry Association; 1994.
18. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Mardsen CD, Calne DB, Golgstein M, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-164.
19. Sweet RA, De Sensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci 1993;5:56-60. (Pubitemid 23073811)
20. Schwab RS, England RC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease. Edinburgh, UK: Livingstone; 1969:152-157.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinical. J Psychiatr Res 1975;12:189-198.
22. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
23. Andreasen N. Scale for the Assessment of Positive Symptoms. Iowa City, IA: University of Iowa College of Medicine; 1984.
24. Guy W. Early Clinical Drug Evaluation Unit (ECDEU). Publication no 76-338. Rockville: National Institute of Mental Health; 1976.
25. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
26. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-695. (Pubitemid 38526677)
27. Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009;113:112-121.
28. Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson's disease. J Pharm Pract 2011;24(6):534-540.
29. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-794.
30. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445. (Pubitemid 35266735)
31. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-156. (Pubitemid 39121725)
32. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006;29:331-337. (Pubitemid 44729944)
33. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963. (Pubitemid 41419510)
34. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-318. (Pubitemid 46569682)
35. Rich S, Friedman JH, Ott B. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatr 1995;56:556-559. (Pubitemid 26001766)
36. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15:1230-1237.
37. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004;27:4-5. (Pubitemid 38280379)
38. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-2081. (Pubitemid 46140415)
39. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999;353:2041-2042.
40. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761. (Pubitemid 36737069)
41. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. Mov Disord 2008;23:1541-1545.